

Company registration number: 758084

Streamvale Pharma Limited
Unaudited abridged financial statements
for the financial year ended 31 July 2025

Streamvale Pharma Limited

Contents

	Page
Director's responsibilities statement	1
Balance sheet	2 - 3
Notes to the abridged financial statements	4 - 6

Streamvale Pharma Limited

Director's responsibilities statement

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Director's Responsibilities Statement accompanying those financial statements.


The director is responsible for preparing the director's report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under the law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless she is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable her to ensure that the financial statements and director's report comply with the She is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


.....
Sandra Morrissey
Director

Date 10th Feb 2025

Streamvale Pharma Limited

Balance Sheet As at 31 July 2025

	Note	2025 €	€	2024 €	€
Fixed assets					
Financial assets		2,843,119		-	
			2,843,119		-
Current assets					
Debtors		-		18,702	
Cash at bank and in hand		400		20,198	
		400		38,900	
Creditors: amounts falling due within one year	5	(62,524)		(38,800)	
Net current (liabilities)/assets			(62,124)		100
Total assets less current liabilities			2,780,995		100
Creditors: amounts falling due after more than one year	6	(688,806)			-
Net assets			2,092,189		100
Capital and reserves					
Called up share capital presented as equity		1,686,100			100
Profit and loss account		406,089			-
Shareholder funds			2,092,189		100

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

The notes on pages 4 to 6 form part of these abridged financial statements.

Streamvale Pharma Limited

Balance Sheet As at 31 July 2025

I, as director of Streamvale Pharma Limited state that:

- the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- the shareholder of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

These abridged financial statements were approved by the director of the company on10/2/2026..... and signed by:


.....
Sandra Morrissey
Director

.....

The notes on pages 4 to 6 form part of these abridged financial statements.

Streamvale Pharma Limited

Notes to the abridged financial statements Financial year ended 31 July 2025

1. Accounting policies and measurement bases

Basis of preparation

The financial statements have been prepared on the going concern basis, under the historical cost convention and comply with the financial reporting standards of the Financial Reporting Council including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") as adapted by Section 1A of FRS 102 and the Companies Act 2014.

The financial statements are prepared in Euro, which is the functional currency of the entity.

Consolidation

The company qualifies for the small companies regime and has taken advantage of the exemption to prepare consolidated financial statements contained in Section 293 of the Companies Act 2014.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Financial assets

Financial assets are initially recorded at cost, and subsequently stated at cost less any provision for diminution in value. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.

Cash flow statement

The company has availed of the exemption contained in Section 1A of FRS102 and as a result have elected not to prepare a cash flow statement.

Streamvale Pharma Limited

Notes to the abridged financial statements (continued) Financial year ended 31 July 2025

Trade Debtors

Trade and other debtors are recognised initially at transaction price (including transaction costs) unless a financing arrangement exists in which case they are measured at the present value future receipts discounted at a market rate. Subsequently these are measured at amortised cost less any provision for impairment. A provision for impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of receivables. The amount of the provision is the difference between the assets carrying amount and the present value of estimated future cash flows, discounted at the effective interest rate. All movements in the level of the provision required are recognised in the profit and loss.

Cash at bank and on hand

Cash at bank and on hand include cash on hand, demand deposits and other term highly liquid investments regardless of maturity. Bank overdrafts are shown within borrowings in current liabilities on the statement of financial position.

Creditors and accruals

Creditors and accruals are classified as current liabilities if payment is due within one year or less. If not, they are presented as non current liabilities. Trade payables are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Related party transactions

The company discloses transactions with related parties other than with 100% wholly owned group undertakings .

3. Directors remuneration

No remuneration paid to director or secretary in current year or previous period.

4. Appropriations of profit and loss account

	2025	2024
	€	€
At the start of the financial year	-	-
Profit for the financial year	406,089	-
At the end of the financial year	<u>406,089</u>	<u>-</u>

Streamvale Pharma Limited

Notes to the abridged financial statements (continued)
Financial year ended 31 July 2025

5. Creditors: amounts falling due within one year

	2025	2024
	€	€
Amounts owed to credit institutions	62,524	-
Director's Current Account	-	38,800
	62,524	38,800

6. Creditors: amounts falling due after more than one year

	2025	2024
	€	€
Amounts owed to credit institutions	688,806	-
	688,806	-

7. Events after the end of the reporting period

There have been no significant events affecting the company since the year end.

8. Directors transactions

During the financial year the company entered into the following arrangements relating to loans, quasi-loans and credit transactions:

	2025	2024
	€	€
Name of director or other person		
Sandra Morrissey		
At the start of the financial year	38,800	-
Advances made during the financial year	41,015	38,800
Amounts repaid during the financial year	(79,815)	(-)
At the end of the financial year	-	38,800

The above is a loan from the director to the company and is interest free and repayable on demand.

9. Controlling party

Sandra Morrissey owns 100% of the share capital.

10. Approval of financial statements

The board of directors approved these abridged financial statements for issue

on...10/2/2025